Case study: Study published in Clinical and Translational Science on the effects of adiponectin-derived peptide ALY688 in MASH/liver fibrosis of STAM model.
We introduce a case study of pharmacology study of adiponectin-derived peptide ALY688 using our MASH model (STAM™ model).
In this paper, daily subcutaneous administration of ALY688, an adiponectin-derived peptide, was confirmed to treat MASH and prevent the progression of fibrosis.
STAM™ mice are a model in which visceral fat is enlarged and abnormal secretion of adipocytokines occurs. In particular, adiponectin secretion is reduced compared to normal mice, resulting in hypoadiponectinemia.
This paper is the first reported case of a MASH treatment approach targeting adipocytokines using STAM™ mice, and proves that STAM™ mice are a model in which the efficacy of adipocytokines against MASH/fibrosis can be evaluated.
If you are interested in our pharmacology services, including our STAM™ mice, please feel free to contact us.